California § 4127. 4127. (Amended by Stats. 2016, Ch. 484, Sec. 23.)

California Statutes

§ 4127. — 4127. (Amended by Stats. 2016, Ch. 484, Sec. 23.)

California § 4127.

JurisdictionCalifornia

Code BPCBusiness and Professions Code - BPC

Div. 2.DIVISION 2. HEALING ARTS

Ch. 9.CHAPTER 9. Pharmacy

Art. 7.5.ARTICLE 7.5. Sterile Drug Products

This text of California § 4127. (4127. (Amended by Stats. 2016, Ch. 484, Sec. 23.)) is published on Counsel Stack Legal Research, covering California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Cal. Business and Professions Code - BPC Code § 4127. (2026).

Text

(a)A pharmacy that compounds sterile drug products shall possess a sterile compounding pharmacy license as provided in this article.

(b)The board shall adopt regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code) to establish policies, guidelines, and procedures to implement this article.

(c)The board shall review any formal revision to General Chapter 797 of the United States Pharmacopeia and The National Formulary (USP–NF), relating to the compounding of sterile preparations, not later than 90 days after the revision becomes official, to determine whether amendments are necessary for the regulations adopted by the board pursuant to subdivision (b).

Free access — add to your briefcase to read the full text and ask questions with AI

(a)
A pharmacy that compounds sterile drug products shall possess a sterile compounding pharmacy license as provided in this article.
(b)
The board shall adopt regulations in accordance with the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code) to establish policies, guidelines, and procedures to implement this article.
(c)
The board shall review any formal revision to General Chapter 797 of the United States Pharmacopeia and The National Formulary (USP–NF), relating to the compounding of sterile preparations, not later than 90 days after the revision becomes official, to
determine whether amendments are necessary for the regulations adopted by the board pursuant to subdivision (b).